Promising drug trodelvy tested as first defense against aggressive breast cancer
NCT ID NCT07299409
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial is testing the drug sacituzumab govitecan (Trodelvy) as a first treatment for people with advanced triple-negative breast cancer who haven't had prior therapy for advanced disease. Researchers want to see if the drug can shrink tumors or slow the cancer's growth. The study will also compare how well the drug works in different genetic subtypes of the cancer. About 24 adults will take part, receiving the drug intravenously on days 1 and 8 of each 21-day cycle.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
sacituzumab govitecan (Trodelvy)
What this could lead to
If successful, this could provide a new first-line treatment option for advanced triple-negative breast cancer, potentially slowing disease progression.
What could go wrong
This is a small, early-phase (Phase 2) study with only 24 participants, so results may not apply to all patients. The drug may cause side effects like nausea, diarrhea, or low blood cell counts.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
BC Cancer - Vancouver Center
Vancouver, British Columbia, V5Z 4E6, Canada
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact